# OnCo record sequoia-pancreatic (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/sequoia-pancreatic/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "sequoia-pancreatic", "NCT02923921" ;
  schema:name "SEQUOIA (pancreatic cancer)"@en ;
  schema:alternateName "SEQUOIA pegilodecakin"@en, "AM0010 phase 3"@en ;
  schema:description "SEQUOIA added the immune cytokine pegilodecakin to second-line FOLFOX chemotherapy for pancreatic cancer and found no gain in survival, progression or response, another negative test of immunotherapy in this cold tumour."@en ;
  schema:url <https://onco.cc/trials/sequoia-pancreatic/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02923921>, <https://doi.org/10.1200/JCO.20.02232> ;
  onco:status "negative" ;
  onco:phase "3" ;
  schema:startDate "2017-03-01" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/pegilodecakin/>, <https://onco.cc/drugs/folfox/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/> ;
  onco:terms <https://onco.cc/terms/cold-vs-hot/>, <https://onco.cc/terms/pancreatic-failed-programmes/> .
